EuroEspes, S.A.
BBME:EEP0.34
EUR
0.00
(0.00%)
ISIN
ES0133421000
Return %
Stock
S&P 500
1Y
0.00
14.20
3Y
0.00
81.12
5Y
-27.66
68.34
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Semi-annual Revenue
EUR
•
in mil. unless spec.Semi-annual Earnings Per Share
EUR
•
in mil. unless spec.Semi-annual Dividends Per Share
EUR
•
in mil. unless spec.Company Description
- CEO
- Joaquín Bueno López
- Full Time Employees
- 24
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- Santa Marta de BabIo s/n Bergondo Spain 15165
- IPO Date
- Jun 21, 2012
- Website
- euroespes.com
- Similar Companies
- Business
- Euroespes S.A. is a Spain-based biotechnology and healthcare company specializing in the prevention, diagnosis, and treatment of central nervous system disorders, including Alzheimer’s and Parkinson’s diseases. The company operates a medical center offering personalized treatment plans and advanced medical services such as genomic medicine, epigenetics, neuropsychology, neuro-ophthalmology, digital diagnosis, diagnostic imaging, clinical analysis, and nursing services. It also provides pharmacogenetics services, including the Human Identification Genetics card, which contains patient DNA profiles to guide personalized pharmacogenetic treatments. Euroespes is active in research and development in biochemistry, health biotechnology, epigenetics, pharmacogenomics, and nutraceuticals, with notable product lines including nutraceutical bioproducts derived from marine, vegetal, animal, and hybrid sources marketed under branded compounds like lipofishins and proteolipins. These products target diseases such as neurodegenerative disorders, cancer, metabolic syndromes, and immunological deficiencies. The company also offers industrial lyophilization services, drug primary screening, vaccine development, preclinical and toxicological studies, clinical trials, and supports CRO partnerships. Euroespes maintains operations primarily in Spain, with its headquarters and biomedical research center located in Bergondo, A Coruña. Founded in 1991, the company serves both domestic and international markets with its medical and biotechnological services and products. It operates through subsidiaries including Euroespes Biotecnologia SA, Distribuidora de Productos SL, and Ebiotec Pharma SL. Recent major developments include the launch and commercialization of novel nutraceutical products with immunomodulatory properties, such as DefenVid, a lipofishin-based supplement designed to enhance immune system resilience. The company continues to expand its personalized medicine platform by advancing its pharmacogenetic smart card technology and updating its EuroPharmaGenics database, facilitating tailored drug therapies. Additionally, Euroespes has maintained focus on expanding its clinical and biotechnological research capabilities through internal projects and partnerships, reinforcing its position as a leader in genomic medicine specialized in nervous system diseases. Euroespes S.A. operates in the healthcare provision and life sciences sector, primarily targeting patients with neurodegenerative and other prevalent diseases, while also engaging pharmaceutical and nutrition industries through its product development and research services. The company reported revenues of around €3.3 million in the trailing twelve months with ongoing investments in innovative biomedical solutions and personalized healthcare technologies. This comprehensive scope of product offerings and recent strategic enhancements position Euroespes as a key player in biotechnology and medical services related to brain disorders and personalized genomic medicine in Spain and beyond.